THE BASICS OF CHEMOEMBOLIZATION

Cover Page

Abstract


Chemoembolization has advantages over systemic chemotherapy as increase in drug concentration, time of exposition and decrease in systemic adverse effects.


About the authors

D G Gitelson

National Research Center for Hematology, Moscow, 125167, Russia

Author for correspondence.
Email: gitelson@rambler.ru
Moscow, 125167, Russia

interventional radiologist of the National Research Center for Hematology

D A Rogov

National Research Center for Hematology, Moscow, 125167, Russia

Email: konovalov_oe@rudn.university
126167, Москва, Россия

A E Vasiliev

National Research Center for Hematology, Moscow, 125167, Russia

Email: konovalov_oe@rudn.university
126167, Москва, Россия

E A Gitelson

RUDN University, Moscow, 117198, Russia

Email: konovalov_oe@rudn.university

References

  1. Dolgushin B. I., Patutko Yu. I., Virshke E. R., Trofimov I. A., Cherkasov V. A., Kukushkin A. V., Kosirev V. Yu. & Sergeeva O. N. Arterialnaya himioembolizaciya mikrosferami, perenosyashimi dok-sorubicin, v lechenii bolnih gepatocellularnim rakom. Predvaritelnie resultati. Anali hirurgicheskoi gepatologii. 2009. Т. 14, N 2. С. 53—58.
  2. Komov D. V., Roshin E. M., Kuchinskii G. A., Dolgushin B. I. & Virshke E. R. Itogi pervoi fazi klinicheskih issledovanii kompleksa doxorubicin-estron u bolnih so zlokachestvennimi novoobra-zovaniyami pecheni pri himiembolizacii c lipiodolom. Vestnik ONC AMN Rossii. 1997. N 4. С. 34—37.
  3. Abdel-Rahman O. M. & Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepa-tocellular carcinoma. Cochrane Database Syst Rev. 2016. N 2. CD 011313.
  4. Arciero C. A. & Sigurdson E.R. Liver-directed therapies for hepatocellular carcinoma. J Natl Compr Canc Netw. 2006. V. 4. N 8. P. 768—774.
  5. Arciero C. A. & Sigurdson E. R. Liver-directed therapies for patients with primary liver cancer and hepatic metastases. Curr Treat Options Oncol. 2006. V. 7. N 5. P. 399—409.
  6. Brown D.B. & Gould J. E. Practice building in interventional oncology. Tech Vasc Interv Radiol. 2006. V. 9. N 3. P. 90—95.
  7. Gamma C., Schepis F., Orlando A. et al. Transarterial chemoembolization for unresectable hepato-cellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002. V. 224. P. 47—54.
  8. Granov A. M., Tarazov P. G., Granov D. A., Polikarpov A. A. & Oleshchuk N. V. Successful treat-ment of patient with recurrent hepatocellular carcinoma. Vestn Khir Im I I Grek. 2015. V. 1. N 2. P. 98—100.
  9. Guan Y. S., He Q. & Wang M. Q. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol. 2012. 480650.
  10. Huang K., Zhou Q., Wang R., Cheng D. & Ma Y. Doxorubicin-eluting beads versus conventional tran-sarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014. V. 29. N 5. P. 920—925.
  11. Kurup A. N. & Callstrom M. R. Ablation of musculoskeletal metastases: pain palliation, fracture risk reduction, and oligometastatic disease. Tech Vasc Interv Radiol. 2013. V. 16. N 4. P. 253—261.
  12. Llovet J. M. & Bruix J. Systematic review of randomized trials for unresectable hepatocellular carci-noma: Chemoembolization improves survival. Hepatology. 2003. V. 37. P. 429—442.
  13. Llovet J. M. & Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial emboliza-tion. Radiology. 2004. V. 2. N 1. P. 300—301.
  14. Llovet J. M., Real M. I., Montaña X., Planas R., Coll S., Aponte J., Ayuso C., Sala M., Muchart J., Solà R., Rodés J. & Bruix J. Barcelona Liver Cancer Group. Arterial embolisation or chemoemboli-sation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a random-ised controlled trial. Lancet. 2002. V. 18. P. 1734—1739.
  15. Lo C. M., Ngan H., Tso W. K. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002. V. 35. P. 1164—1171.
  16. Malagari K., Chatzimichael K., Alexopoulou E. et al. Transarterial chemoembolization. World J Gastroenterol. 2015.V. 2. № 9. P. 420—424.
  17. Miraglia R., Pietrosi G., Maruzzelli L., Petridis I., Caruso S., Marrone G., Mamone G., Vizzini G., Luca A. & Gridelli B. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol. 2007. V. 7. N 13. P. 2952—2955.
  18. Park Y. N. & Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol. 2006. V. 45. N 5. P. 734—743.
  19. Pereira P. L. & Masala S. Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Standards of practice: guidelines for thermal ablation of primary and secondary lung tu-mors. Cardiovasc Intervent Radiol. 2012. V. 35. N 2. P. 247—254.
  20. Rammohan A., Sathyanesan J., Ramaswami S., Lakshmanan A., Senthil-Kumar P., Srini¬vasan U. P., Ramasamy R. & Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol. 2012. V. 28. № 4. P. 405—412.
  21. The Royal College of Radiologists UK. Interventional Oncology: Guidance for Service delivery 2013—2016.
  22. Tian X., Dai Y., Wang D. Q., Zhang L., Sui C. G., Meng F. D., Jiang S. Y., Liu Y. P. & Jiang Y. H. Tran-sarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. Drug Des Devel Ther. 2015. V 10. N 9. P. 4431—4440.
  23. Varela M., Real M. I., Burrel M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. Hepatology. 2007. V. 46. N 3. P. 474—481.
  24. Bruix J., Sala M. & Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004. V. 5. N 1. P. 179—188.
  25. Kasugai H., Kojima J., Tatsuta M., Okuda S., Sasaki Y., Imaoka S., Fujita M. & Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with in-traarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989. V. 97. N 4. P. 965—971.
  26. Pelletier G., Roche A., Ink O., Anciaux M. L., Derhy S., Rougier P., Lenoir C., Attali P. & Etienne J. P. A randomized trial of hepatic arterial chemoembolization in patients with unre¬sectable hepatocel-lular carcinoma. J Hepatol. 1990. V. 11. N 2. P. 181—184.
  27. Kawai S., Okamura J., Ogawa M., Ohashi Y., Tani M., Inoue J., Kawarada Y., Kusano M., Kubo Y. & Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carci-noma — a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992. V. 31. P. 1—6.
  28. Okamura J., Kawai S., Ogawa M., Ohashi Y., Tani M., Inoue J., Kawarada Y., Kusano M., Kubo Y. & Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carci-noma--a comparison of L-TAE with Farmorubicin and L-TAE with adriamycin (second coopera-tive study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992. V. 31. P. 20—24.
  29. Watanabe S., Nishioka M., Ohta Y., Ogawa N., Ito S. & Yamamoto Y. Prospective and random-ized controlled study of chemoembolization therapy in patients with advanced hepatocellular car-cinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol. 1994. V. 33. P. 93—96.

Statistics

Views

Abstract - 172

PDF (Russian) - 814

Cited-By


PlumX

Dimensions


Copyright (c) 2017 Gitelson D.G., Rogov D.A., Vasiliev A.E., Gitelson E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies